Stifel raised the firm’s price target on Astrana Health to $60 from $48 and keeps a Buy rating on the shares ahead of the Q2 earnings report due on Wednesday, August 7. The firm expects the call to be focused on second half medical cost trends in Medicare/Medicaid, the strategic rationale around the recent Collaborative Health Systems acquisition, and progress in transitioning to full risk, the analyst tells investors in a preview.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH:
- Astrana Health price target raised to $60 from $50 at BTIG
- Astrana Health Announces Major Acquisitions and Earnout Agreement
- Astrana Health to acquire Collaborative Health Systems, no terms disclosed
- Astrana Health and Elation Health partner in infrastructure solution
- Astrana Health and Anthem Blue Cross partner in California
Questions or Comments about the article? Write to editor@tipranks.com